Progress on targeting TRAIL's receptor as antitumor strategy.
- Author:
Shu-Zhen CHEN
1
Author Information
1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. bjcsz@yahoo.com.cn
- Publication Type:Journal Article
- MeSH:
Animals;
Antineoplastic Agents;
pharmacology;
therapeutic use;
Apoptosis;
drug effects;
Drug Delivery Systems;
GPI-Linked Proteins;
genetics;
metabolism;
Genetic Therapy;
Humans;
Neoplasms;
metabolism;
pathology;
therapy;
Receptors, TNF-Related Apoptosis-Inducing Ligand;
classification;
genetics;
metabolism;
Receptors, Tumor Necrosis Factor, Member 10c;
Signal Transduction;
TNF-Related Apoptosis-Inducing Ligand;
genetics;
metabolism;
pharmacology;
Tumor Necrosis Factor Decoy Receptors;
genetics;
metabolism
- From:
Acta Pharmaceutica Sinica
2009;44(12):1336-1342
- CountryChina
- Language:Chinese
-
Abstract:
There exist two major apoptotic signaling pathways: the intrinsic mitochondria-mediated pathway, and the extrinsic death receptor-induced pathway. TNF-related apoptosis-inducing ligand (TRAIL), which is the ligand for death receptor 4 (DR4) and death receptor 5 (DR5) and induces apoptosis by ligation with DR4 or DR5. We review the characteristic of TRAIL and its receptors, the mechanism of apoptosis induced by TRAIL, the distribution of death receptors in cancer, and applications and prospects of TRAIL signaling pathway in the treatment of cancer.
